Mar 13 |
Clearmind Medicine receives nod for delisting of shares from Canadian Securities Exchange
|
Mar 13 |
Clearmind Medicine Obtains Clearance for its Psychedelic- Based Alcoholism Clinical Trial
|
Mar 13 |
Clearmind Medicine Received Approval for a Voluntary Delisting of its Common Shares From the Canadian Securities Exchange
|
Mar 12 |
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
|
Feb 27 |
SciSparc gains as Clearmind partnership yields 3 new international patent applications
|
Feb 27 |
SciSparc-Clearmind Partnership Yields Three New International Patent Applications for MDMA, Ibogaine and Ketamine Compounds
|
Feb 27 |
Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds
|
Feb 23 |
Clearmind Medicine Receives Approval to Commence its Phase I/IIa Clinical Trial of CMND-100 for Alcohol Use Disorder
|
Feb 20 |
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds
|
Feb 20 |
Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds
|